Federated Hermes
BMRN icon

Federated Hermes’s BioMarin Pharmaceuticals BMRN Stock Holding History

Federated Hermes’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20,000
Closed -$1.82M – 2141
2017
Q2 		$1.82M Hold
20,000
– – 0.01% 961
2017
Q1 		$1.76M Hold
20,000
– – 0.01% 956
2016
Q4 		$1.65M Buy
+20,000
New +$1.72M 0.01% 944

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes's BMRN Position: Q1 2026 in Review

Federated Hermes reduced its BioMarin Pharmaceuticals (BMRN) stake by 46% in Q1 2026, selling an estimated $8.03M and leaving 162,097 shares worth $9.16M. The position accounts for 0.01% of the portfolio, ranked #665.

Federated Hermes first reported a position in BMRN in Q1 2015 and has held it in 26 quarters since. The position peaked at $17.8M in Q4 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Federated Hermes held 162,097 shares of BioMarin Pharmaceuticals worth $9.16M as of Q1 2026.
  • Federated Hermes sold 137,663 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $8.03M.
  • BioMarin Pharmaceuticals made up 0.01% of Federated Hermes's portfolio in Q1 2026, its #665 holding.
  • Federated Hermes first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 26 quarters since.
  • Federated Hermes's BioMarin Pharmaceuticals position peaked at $17.8M in Q4 2025.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.